Bio-Rad Laboratories Inc. (BIO)
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Bio-Rad (BIO) International Revenue Performance Explored
Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
BIO Stock Might Rise Following the Offer to Acquire Stilla
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Conference Call Participants Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Tycho Peterson - Jefferies Operator Thank you for standing by. My name is Prila [ph] and I will be your conference operator today.
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago.
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors.
New Jersey Based Biometric and Cyber Security Solutions Provider BIO-key to Present and Participate at DealFlow's Atlantic City Microcap Conference Jan. 29th and 30th
ATLANTIC CITY, NJ and HOLMDEL, NJ / ACCESSWIRE / January 10, 2025 / BIO-key® International, Inc. (NASDAQ:BKYI), an innovative provider of identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless, and phish-resistant authentication, will present and meet with investors at DealFlow Event's Microcap Conference on Wednesday, January 29th & 30th at the Borgata hotel in Atlantic City, New Jersey. CEO Mike DePasquale will present at 2:00pm ET on Wednesday and be available for meetings both days.
